Neuphoria Therapeutics (NEUP) Equity Average (2021 - 2025)
Historic Equity Average for Neuphoria Therapeutics (NEUP) over the last 5 years, with Q4 2025 value amounting to $21.1 million.
- Neuphoria Therapeutics' Equity Average rose 3696.71% to $21.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.1 million, marking a year-over-year increase of 3696.71%. This contributed to the annual value of $31.5 million for FY2023, which is N/A changed from last year.
- Latest data reveals that Neuphoria Therapeutics reported Equity Average of $21.1 million as of Q4 2025, which was up 3696.71% from $15.8 million recorded in Q3 2025.
- Neuphoria Therapeutics' 5-year Equity Average high stood at $42.3 million for Q2 2022, and its period low was $15.4 million during Q4 2024.
- Its 5-year average for Equity Average is $23.8 million, with a median of $21.1 million in 2025.
- In the last 5 years, Neuphoria Therapeutics' Equity Average plummeted by 2569.75% in 2023 and then soared by 3696.71% in 2025.
- Neuphoria Therapeutics' Equity Average (Quarter) stood at $26.1 million in 2021, then skyrocketed by 62.14% to $42.3 million in 2022, then dropped by 25.7% to $31.5 million in 2023, then tumbled by 51.02% to $15.4 million in 2024, then soared by 36.97% to $21.1 million in 2025.
- Its Equity Average stands at $21.1 million for Q4 2025, versus $15.8 million for Q3 2025 and $22.5 million for Q2 2025.